

November 06, 2023

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Subject: Investors Presentation Q2 FY24 – Orchid Pharma Limited (“the Company”)

Dear Sir/Madam,

This is in continuation to our earlier announcement dated November 02, 2023.

In accordance to the requirement of Regulation 30 of SEBI (Listing Obligation and Disclosures Requirement) Regulations, 2015, please find enclosed copy of the Investor Presentation on the financial performance of the Company for quarter ended September 30, 2023.

Copy of the Investor Presentation is also made available on the website of the Company at www.orchidpharma.com

You are requested to take the above on your record.

Thanking You,
For **Orchid Pharma Limited**

MARINA

PETER

Marina Peter

Company Secretary & Compliance Officer

Encl. as above

Digitally signed by
MARINA PETER
Date: 2023.11.06
14:54:53 +05'30'

Q2-FY24 Results



SAFE HARBOR

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Orchid Pharma Ltd** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness


Financial Highlights

(Rs/Crore)`	Q2-2024	Q2-2023	Change %	6M-30 th Sep'24	6M-30 th Sep'23	Change %
Sales	198.8	165.2	+20%	381.7	296.2	+29%
Other Income	7.5	5.8	+29%	8.8	8.8	+0%
COGS	122.4	100.3		234.4	170.1	
Employee Exp	17.2	17.7	-3%	33.4	32.3	+3%
Other Exp	35.5	29.4		68.0	63.5	
EBITDA	31.2	18.9	+65%	54.7	34.2	+60%
% to Sales	16%	11%		14%	12%	
Non Op-Income	0.7	4.7		1.3	4.9	
Interest	3.8	9.2	-59%	9.3	17.1	-46%
Depreciation	7.8	17.7	-56%	15.6	39.4	-60%
PBT	20.3	-3.3		31.1	-17.4	
PAT	20.3	-3.3		31.1	-17.4	


Status of Term Loans

Your Company has fully paid all the term loan taken from Banks now.


TOTAL INCOME




EBITDA




PAT



EXPENSE BREAKUP



LEVERAGE



SUMMARY RESULTS

				Rs. In Cr.
Particulars	FY 2022-23	FY 2021-22	HY1-FY23	HY1-FY24
Net Sales/Income from Operations	666	557	296	382
Other Income	19	9	9	10
Total Income	685	566	305	392
Raw Material Cost	385	314	170	234
Employee benefit expenses	65	60	32	33
Finance Costs	32	32	17	9
Depreciation & amortization Expenses	55	87	39	16
Other expenses	132	125	64	68
Total Expenses	669	619	322	361
Profit/Loss before exceptional items	16	-53	-17	31

Thank You!

OrchidPharma
— A Dhanuka Group Company —

© Copyright OrchidPharma Ltd. All Rights Reserved

11